P1.17-32 The 8th Editions of the AJCC Staging System in Terms of Predicting Recurrence and Survival in Resected NSCLC Long-Term Survivors

Abstract Background The objective of this study was to investigate the survival outcomes of surgical margin width in intrahepatic cholangiocarcinoma (ICC). Methods Between November 2011 and August 2017, patients who underwent hepatectomy for ICC were collected from 13 major hepatopancreatobiliary centers in China. The survival outcomes for patients who underwent wide margin hepatectomy (WMH) were compared with those who underwent narrow margin hepatectomy (NMH) using the 1:1 propensity score matching (PSM). Results Among 478 included patients, 195 (40.8%) underwent WMH whereas 283 (59.2%) underwent NMH. PSM yielded 79 matched patients with similar baseline characteristics. Patients underwent WMH had a significant better OS and DFS compared with those underwent NMH (before PSM: median OS 27 vs 17 months, P < 0.05; median DFS 15 vs 8 months, P = 0.001, after PSM: median OS 41 vs 22 months, p < 0.05; median DFS 16 vs 10 months, p < 0.05). However, subgroup analysis based on the AJCC staging system, WMH could only improve the survival outcomes in AJCC I ICC patients (Stage I: OS, DFS, P<0.05). Conclusions Surgeons should strive to achieve a wide surgical margin for patients with AJCC I ICC to optimize the long-term outcome.

Download Full-text

Mo1041 Long-Term Survival Outcomes After Incorporation of Serum Pretreatment AFP Levels Into AJCC Staging System in Hepatocellular Carcinoma

Gastroenterology ◽

10.1016/s0016-5085(14)63610-6 ◽

2014 ◽

Vol 146 (5) ◽

pp. S-993-S-994

Author(s):

Sumeet Munjal ◽

Chetasi Talati ◽

Pragatheeshwar Thirunavukarasu ◽

Kristopher Attwood ◽

Renuka Iyer ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Staging System ◽

Survival Outcomes ◽

Term Survival ◽

Long Term Survival ◽

Ajcc Staging System ◽

Ajcc Staging

Download Full-text

Revisiting the AJCC staging system of adrenocortical carcinoma

Journal of Endocrinological Investigation ◽

10.1007/s40618-021-01618-0 ◽

2021 ◽

Author(s):

O. Abdel-Rahman

Keyword(s):

Adrenocortical Carcinoma ◽

Staging System ◽

Ajcc Staging System ◽

Ajcc Staging

Download Full-text

A Single-Institution Validation of the AJCC Staging System for Stage IV Melanoma

Annals of Surgical Oncology ◽

10.1245/s10434-008-9915-0 ◽

2008 ◽

Vol 15 (7) ◽

pp. 2034-2041 ◽

Cited By ~ 32

Author(s):

Heather B. Neuman ◽

Ami Patel ◽

Nicole Ishill ◽

Christine Hanlon ◽

Mary Sue Brady ◽

...

Keyword(s):

Stage Iv ◽

Staging System ◽

Single Institution ◽

Ajcc Staging System ◽

Ajcc Staging ◽

Stage Iv Melanoma

Download Full-text

Prognostic value of subclassification (pT2 stage) of pathologically organ-confined prostate cancer: Confirmation of the changes introduced in the 8th edition of the American Joint Committee on Cancer (AJCC) staging system

Archivio Italiano di Urologia e Andrologia ◽

10.4081/aiua.2018.3.191 ◽

2018 ◽

Vol 90 (3) ◽

pp. 191-194 ◽

Cited By ~ 2

Author(s):

Hugo Pontes Antunes ◽

Belmiro Parada ◽

João Carvalho ◽

Miguel Eliseu ◽

Roberto Jarimba ◽

...

Keyword(s):

Prostate Cancer ◽

Specific Antigen ◽

Staging System ◽

Distant Metastases ◽

Grade Group ◽

Pathological Evaluation ◽

Ajcc Staging System ◽

Oncological Results ◽

Ajcc Staging ◽

8Th Edition

Objective: The last edition of the AJCC staging system eliminated the pT2 subclassification of prostate cancer (PCa). Our objective was to evaluate the association of pT2 subclassification with the oncological results of patients with PCa who underwent radical prostatectomy (RP). Material and methods: We evaluated 367 patients who underwent RP between 2009 and 2016, with pT2 disease in the final pathological evaluation. We assessed differences in rates of biochemical recurrence (BCR), metastasis and mortality between T2 substages (pT2a/b vs pT2c). Results: Fifty-three (14.4%) patients presented pT2a/b disease and 314 (85.6%) pT2c disease. The mean follow-up time was 4.9 ± 2.6 years. Grade group scores (p = 0.1) and prostate specific antigen (PSA) (p = 0.2) did not differed between pT2 substages. The rate of BCR in pT2a/b and pT2c patients was 11.3% and 18.2%, respectively (p = 0.2). Five (9.4%) patients with pT2a/b and 45 (14.3%) with pT2c substage underwent salvage radiotherapy (p = 0.3). The rate of positive surgical margins did not differ between groups (p = 0.2). Seven (2.2%) patients with pT2c had lymph nodes or distant metastases. The overall survival was 92.5% and 93.6% in pT2a/b and pT2c, respectively (p = 0.2). Conclusion: Our results are in accordance with the changes introduced in the 8th edition of the AJCC staging system in which the pT2 subclassification was eliminated.

Download Full-text

Concomitant Chemoradiation in Locally Advanced Laryngeal Cancer

International Journal of Head and Neck Surgery ◽

10.5005/jp-journals-10001-1030 ◽

2010 ◽

Vol 1 (3) ◽

pp. 153-160

Author(s):

Arif Jamshed ◽

Raza Hussain ◽

Sarah Jamshed ◽

Aamir Ali Syed ◽

Asif Loya ◽

...

Keyword(s):

Laryngeal Cancer ◽

Univariate Analysis ◽

Locally Advanced ◽

Survival Rates ◽

Staging System ◽

Nodal Disease ◽

Free Survival ◽

Concomitant Chemoradiation ◽

Ajcc Staging System ◽

Ajcc Staging

Abstract Introduction Despite the acceptance of concomitant chemoradiation (CRT) as an alternative to total laryngectomy (TL) in locally advanced laryngeal cancer (LALC), laryngeal preservation is sparingly recommended in developing countries. We report on prognostic factors and survival in T3/T4 laryngeal cancer treated with concomitant CRT at Shaukat Khanum Memorial Cancer Hospital and Research Center (SKMCH and RC) to provide comparison with other geographic locations. Material and Methods During the period November 2003-April 2009, 101 patients with biopsy proven untreated LALC underwent concurrent CRT treatment at SKMCH and RC. According to AJCC staging system (6th edition) 41 had T3 and 60 patients had T4 disease. Radiation dose to the larynx was 70 Gy in 35 fractions with concomitant cisplatin. Induction chemotherapy was given to 42 patients. Thirty-one patients required tracheotomy either before or during concomitant CRT. Results Actuarial overall survival and laryngectomy free survival (LFS) for the whole group at 5 years were 54% (95% CI; 48-60) and 47% (95% CI; 42-52) respectively. Median LFS was 4.17 years. On univariate analysis patients with T4 tumors (p = 0.04), positive neck nodal disease (p = 0.02), supraglottic site (p = 0.02) and tracheotomy (0.009) had a significantly inferior LFS. Multivariate analysis showed tracheotomy to be the only factor significantly (p = 0.03) related to a higher risk of failure for LFS. Conclusion Survival rates for LALC treated with concomitant CRT in our institution are acceptable. Our study supports the use of TL in patients with compromised airways that require tracheotomy as outcome with concomitant CRT is poor.

Download Full-text